Menuju konten utama
Dengan mendaftar keanggotaan tirto.id, Anda dianggap telah memahami dan menyepakati Kebijakan Privasi.

/DISREGARD RELEASE: Ractigen Therapeutics/

We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued 7:30AM 12-Dec-2025 over PR Newswire, as the release contained erroneous information.

PR Newswire
Terbit 12 Dec 2025 22:10 WIB
/DISREGARD RELEASE: Ractigen Therapeutics/
PR Newswire Asia - Tirto EN
Jadikan tirto.id sumber pilihan pencarian Google

We are advised by Ractigen Therapeutics that journalists and other readers should disregard the news release, Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy, issued 7:30AM12-Dec-2025 over PR Newswire, as the release contained erroneous information.

Sumber: www.prnasia.com

Disclaimer: This press release was supplied by a third party. Tirto is not involved in its preparation and bears no responsibility for its content.

Reporter: PR Newswire
Penulis: PR Newswire
Editor: PR Newswire

Flash News

Populer